Life Saving Drugs Program – Mucopolysaccharidosis type II (MPS II) – Guidelines

These guidelines contain the general, initial and ongoing eligibility requirements to access treatment for mucopolysaccharidosis type II (MPS II) under the Life Saving Drugs Program.

Downloads

Life Saving Drugs Program – Mucopolysaccharidosis type II (MPS II) – Guidelines

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Publication date:
Date last updated:
Publication type:
Guideline
Audience:
Health sector
Language:
English
Description:

These guidelines include:

  • General information about the Life Saving Drugs Program (LSDP)
  • Treatment of mucopolysaccharidosis type II (MPS II) through the LSDP
  • Drugs currently available for the treatment of MPS II through the LSDP
  • Dosage
  • General, initial and ongoing eligibility requirements
  • LSDP funding conditions
  • Exclusion criteria.

Help us improve health.gov.au

If you would like a response please use the enquiries form instead.